Single nucleotide polymorphisms of the APC gene and colorectal cancer risk: a case-control study in Taiwan by Chen, Shee-Ping et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Single nucleotide polymorphisms of the APC gene and colorectal 
cancer risk: a case-control study in Taiwan
Shee-Ping Chen1,2, Shih-Tzu Tsai3, Shu-Wen Jao4, Yen-Lun Huang1,2, Yu-
Chen Chao2, Yi-Lin Chen1,2, Chang-Chieh Wu4, Shinn-Zong Lin*1,2 and 
Horng-Jyh Harn*1,2,5
Address: 1Institute of Medical Sciences, Buddhist Tzu Chi University: 703, Section 3, Chung-Yang Road, 970 Hualien, Taiwan, 2Neuro-Medical 
Scientific Center Departments, Buddhist Tzu Chi General Hospital, Hualien, Taiwan, 3Department of Family Medicine, Buddhist Tzu Chi General 
Hospital, Hualien, Taiwan, 4Department of Surgery, Tri-Service General Hospital, Taipei, Taiwan and 5Department of pathology, Buddhist Tzu Chi 
General Hospital, Hualien, Taiwan
Email: Shee-Ping Chen - asdinap@yahoo.com.tw; Shih-Tzu Tsai - stt.tsai@msa.hinet.net; Shu-Wen Jao - jaosw@ndmctsgh.edu.tw; Yen-
Lun Huang - leaf0731@yahoo.com.tw; Yu-Chen Chao - praise320@yahoo.com.tw; Yi-Lin Chen - sofichen@ms95.url.com.tw; Chang-
Chieh Wu - eric@ndmctsgh.edu.tw; Shinn-Zong Lin* - szlin@tzuchi.org.tw; Horng-Jyh Harn* - duke@tzuchi.com.tw
* Corresponding authors    
Abstract
Background: Colorectal cancer (CRC), which has become especially prevalent in developed
countries, is currently the third highest cause of cancer mortality in Taiwan. Mutation of the
adenomatous polyposis coli (APC) gene, a tumour suppressor, is thought to be an early event in
colorectal tumourigenesis. To date, however, no large-scale screening for APC gene variants in
Chinese subjects has been performed. The present study was undertaken to identify APC gene
variants that are significantly associated with the occurrence of CRC in Taiwanese subjects.
Methods: In order to compare the genotype distribution of variant sites, the full-length APC genes
of 74 healthy individuals and 80 CRC patients were sequenced.
Results: Among the 154 Taiwanese subjects examined in this study, three new mutations, but no
previously reported mutations, were found. One deletion at codon 460 leading to a frameshift and
two missense mutations resulting in p.V1125A and p.S1126R substitutions were identified.
Additionally, three high risk genotypes associated with three single nucleotide polymorphisms and
one low risk genotype at codon 1822 were identified.
Conclusion:  The findings of this case-control study are consistent with the proposal that
Taiwanese subjects differ from other subjects with respect to phenotypic presentation of APC and
CRC risk.
Background
Colorectal cancer (CRC) has increased in incidence over
the past two to three decades and has become especially
prevalent in developed countries. For example, CRC is
currently the second most common form of cancer and
the third leading cause of cancer mortality in the United
States [1]. In Taiwan, CRC has become the fourth most
common form of cancer and the third leading cause of
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death due to cancer. Approximately 10% of CRCs are
attributable to genetic alterations whereas 90% occur spo-
radically [2].
Familial adenomatous polyposis (FAP), a disease inher-
ited as an autosomal dominant, is characterized by the
development of multiple colorectal polyps and possesses
the potential to progress to CRC. FAP is now recognized
to be caused by a functional mutation in the adenomatous
polyposis coli (APC) gene [3,4]. The APC gene is located at
5q21-q22, contains 15 exons, has a corresponding mRNA
of approximately 10 kb, and encodes a large protein with
multiple functional domains. The gene product has been
linked with several important processes including cell
adhesion, maintenance of cytoskeletal integrity and chro-
mosomal stability, and regulation of the cell cycle [5]. Pre-
vious findings are consistent with the proposals that the
APC  gene functions as a tumour suppressor and that
somatic mutations in the APC gene predispose humans to
development of FAP. The loss of APC function is currently
thought to represent an event critical to colorectal
tumourigenesis [6].
Although CRC attributable to mutations of the APC gene
that lead to development of FAP represents less than 1%
of all CRCs, APC germline mutations have close to 100%
penetrance [7]. Exon 15 of the APC gene encompasses
75% of the gene coding sequence and is the most com-
mon mutation site. Over 98% of mutations in this region
are either nonsense or frameshift mutations. The codons
1061 and 1309 are the most common germline mutation
sites, and mutations at either site often result in a
frameshift [8,9]. In addition, two missense germline
mutations of APC are frequently reported. The first is the
p.I1307K variant which is found in Ashkenazi Jews and is
associated with a several-fold increased risk for develop-
ment of multiple adenomas and CRC. The second is
p.E1317Q, the mutation site of which lies between the
first and second 20-amino acid β-catenin binding sites.
This mutation has been proposed to suppress the APC/β-
catenin pathway, thereby predisposing to the develop-
ment of adenomas [10-12].
Somatic mutations in the APC gene are found in over 85%
of sporadic colorectal adenomas and carcinomas [13].
More than 60% of all such mutations are found within the
sequence between codons 1286 and 1513 and termed the
mutation cluster region (MCR) [14]. Two hotspots for
somatic mutations are found at codons 1286 and 1450;
mutations at these sites often result in stop codons [8,9].
Mutations in regions of the MCR encoding the 20-amino
acid  β-catenin binding sites may result in functional
defects in the APC protein [12].
To improve current understanding of the genetics and bio-
logical functions of APC, additional screening of the gene
for single nucleotide polymorphisms (SNPs) or missense
mutations is needed. Furthermore, recognition of such
mutations is essential in determining the inherited risks
for CRC. APC gene variants may present as population-
specific. To date, however, no large-scale screening for
APC  gene variants in Chinese subjects has been con-
ducted. The present case-control study was performed to
characterize SNP mutations of the APC gene in the Tai-
wanese population and to identify the variants that are
significantly associated with the occurrence of CRC.
Methods
Subjects samples
Health examinations were performed for 74 individuals at
the Hualien Tzu Chi Medical Center and for 80 colorectal
cancer patients at the Tri-Service General Hospital. All
subjects were screened for colorectal tumors by colons-
copy and none of them has the family history of CRC.
Written informed consent was obtained from all subjects,
and the study protocol was approved by The Protection of
Human Subjects Institutional Review Board Tzu-Chi Uni-
versity and Hospital, IRB093-54.
The study group was comprised of 80 colorectal cancer
patients and 74 healthy adults. The patient group con-
sisted of 40 (50%) males of 63.6 ± 12.5 years of age (mean
± SD; range, 35–95 years) and 40 (50%) females of 59.2
± 11.0 years of age (mean ± SD; range, 37–80 years). The
mean age ± SD for all patients was 61.5 ± 12.0 years
(range, 35–95 years). The health examination group con-
sisted of 34 (45.3%) males of 55.8 ± 11.5 years of age
(mean ± SD; range, 32–84 years) and 41 (54.7%) females
of 53.0 ± 8.7 years of age (mean ± SD; range, 39–72 years).
The mean age ± SD for all healthy adults was 54.3 ± 10.1
years (range, 32–84 years). In the patient group, there
were 16 (20%) subjects with proximal tumors, 26
(32.5%) subjects with distal tumors, 38 (47.5%) subjects
with rectal tumors, and there were 8 (10%) subjects with
colorectal tumors in Duke's stage A, 24 (30%) in Duke's
stage B, 38 (47.5%) in Duke's stage C and 10 (12.5%) in
Duke's stage D.
DNA extraction
Genomic DNA was extracted from 10 ml of whole blood
through use of the Puregene Genomic DNA Purification
Kit (Gentra Systems, Inc., Minneapolis, MN, USA). The
extracted DNA was quantified with a DU 640 spectropho-
tometer (Beckman Instruments, Inc., Fullerton, CA, USA).
Gene amplification and DHPLC
The coding region of the APC gene was divided into 28
segments, each of which was amplified separately using
the polymerase chain reaction (PCR). The primer pairsBMC Cancer 2006, 6:83 http://www.biomedcentral.com/1471-2407/6/83
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used in this study were designed for both PCR and dena-
turing high performance liquid chromatography
(DHPLC; Transgenomic, Inc., Omaha, NE, USA) as previ-
ously described [15]. All samples were amplified in 50-µl
of a reaction mixture containing 50 ng genomic DNA, 10
mM Tris-HCl, 50 mM KCl, 2.5 mM MgCl2, 0.2 mM of each
dNTP, 200 mM of each primer, and 0.15 U AmpliTaq
Gold DNA polymerase (Applied Biosystems; Roche
Molecular Systems, Inc., Branchburg, NJ, USA). The ther-
mal cycling profile was composed of an initial denatura-
tion step at 95°C for 10 min, 35 cycles of 30 sec of
denaturation at 95°C, 30 sec of annealing at 55°C, and 1
min of extension at 72°C, with a final 10-min extension
step at 72°C. DNA samples amplified from the same
regions of APC genes were subjected to DHPLC and com-
pared. When observed peaks differed in sharpness or
appeared with more than 0.08 sec of difference from the
main peak, potentially different DNA sequences were sus-
pected. Such samples were therefore subjected to sequenc-
ing.
DNA sequencing
Sequencing reactions were performed with the BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, CA, USA). Each sequencing reaction was
amplified in a 10-µl reaction mixture containing 10–30
ng amplified DNA. The thermal cycling profile consisted
of an initial denaturation step at 95°C for 10 sec, 25 cycles
of 10 sec of denaturation at 95°C, 5 sec of annealing at
50°C, and 1 min of extension at 60°C. Primers used for
direct sequencing reactions were identical to those used in
the amplification reactions. Nucleotide sequences of both
strands were determined with an ABI Prism 3100 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA)
equipped with a long-read sequencing capillary and a
POP-4 sequencing polymer.
Data analysis
The sequence data collected from the ABI 3100 Genetic
Analyzer were analyzed by software programs from
Applied Biosystems. The analyzed sequence data were
aligned through the use of BioEdit 7.0.5 software [16].
The Chi-square tests for Hardy-Weinberg equilibrium, the
Chi-square and Fisher's exact tests for differences between
the patient and health examination groups, and logistic
regression analyses for odds ratios (without adjusting for
other variables) were processed by SAS 9.1.
Results
When the coding regions of APC genes of all 154 subjects
enrolled in the study were sequenced, 12 SNPs and 1 dele-
tion mutation were identified (Table 1). Of these variants,
8 SNPs were located within exon 15, 2 SNPs within exon
11, 1 SNP within exon 9, 1 SNP within exon 13, and 1
deletion within exon 10. Of the 12 SNPs, 9 are silent sub-
stitutions and 3 are responsible for the amino acid
changes p.V1125A, p.S1126R and p.D1822V. Ten SNPs
were identified in the health examination group and 2 of
these SNPs, g.1488A>T and g.3378C>G, were not found
in the patient group. Ten SNPs and 1 deletion mutation
were found in the patient group and 3 of these variants,
g.1050T>G, g.1378delG and g.4725A>G, were not found
in the health examination group (Table 1).
The single base pair deletion, g.1378delG, which is
located in exon 10, was found only in one individual in
the patient group. This subject presented with a hetero-
zygous genotype, confirmed by repeated forward and
reverse sequencing. Prevalence of this mutation, which is
reported here for the first time, was not significantly dif-
ferent between the patient and health examination
groups.
Of the 3 observed missense substitutions, p.V1125A and
p.S1126R represent variants not previously reported.
p.V1125A was identified in three subjects in the patient
group and in one subject in the health examination group,
but p.S1126R was found only in the health examination
group. However, the prevalence of these variants did not
differ significantly between the patient and health exami-
nation groups. The characteristics of the subjects in the
patient group with g.1378delG deletion or g.3374T>C
(p.V1125A) are listed in Table 2. Prevalence of the
p.D1822V variant, which has been observed previously
[17-19], was significantly different between the patient
and health examination groups. When this variant was
analyzed further by determination of the odds ratio, a low
risk for CRC was observed for subjects displaying the AT
genotype (Table 3).
Of the 12 SNPs identified, only g.1458T>C and observed
within the patient group displayed significant deviation
from Hardy-Weinberg equilibrium (p = 0.002). To ascer-
tain whether differences in the genotype distribution
existed between the health examination group and patient
group at these SNP sites, the Chi-square test and the
Fisher's Exact test were performed. Significant differences
were observed at g.1458T>C (p = 0.0012), g.4479G>A, (p
= 0.0057), g.5268T>G (p = 0.0023). Analysis of the odds
ratio for each genotype at these three sites revealed that
g.1458T>C and g.4479G>A were significant and
g.5268T>G was close to significant associated with a
higher risk genotype (Table 3).
Discussion
In this case-control study involving the screening of 74
healthy Taiwanese adults and 80 Taiwanese CRC patients
for germline variants throughout the entire coding region
of the APC gene, three new mutations were identified. No
mutations reported in previous studies, including those atBMC Cancer 2006, 6:83 http://www.biomedcentral.com/1471-2407/6/83
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codons 1061 and 1309 which are considered the most
common mutation sites, were identified. The absence in
these Taiwanese subjects of the Caucasian-specific muta-
tions p.E1317Q and p.I1307K that are known to cause
missense changes is in accord with the findings of Guo et
al. [20]. Additionally, Asian-specific variants such as the
odd mutations reported in a Japanese study [21] were not
displayed by any of the Taiwanese subjects in the present
study. These observations are consistent with the propos-
als that the different presentations of the APC  gene in
these Taiwanese subjects are due to population differences
and that the new mutations found in this study represent
Taiwanese-specific hotspot mutations.
The three new mutations identified in the present study
include a one base pair deletion and two missense substi-
tutions. The one base pair deletion occurs at codon 460 of
exon 10 and will cause a frameshift resulting in expression
of a truncated protein. The two missense substitutions,
p.V1125A and p.S1126R, occur in close proximity to the
first 15-amino acid β-catenin binding repeat (amino acids
1136–1151) located at the center of the β-catenin down-
regulation domain. Such substitutions may result in dis-
ruption of the putative cell signaling function of the APC
protein; however, this needs to be demonstrated experi-
mentally. It should be noted that all three mutations pre-
sented with low frequency in subject population of the
present study and that the p.S1126R mutation was
observed only in the health examination group. The sites
at which these mutations occur, therefore, may not repre-
sent hotspots commonly associated with CRC. Neverthe-
less, the presence of these mutations may result in
development of CRC. Long-term monitoring of persons
who present with these mutations is therefore considered
essential.
The frequency distribution of the 13 variants identified in
the present study differed significantly between the health
examination group and patient group at g.1458T>C,
g.4479G>A, g.5268T>G and g.5465A>T (Table 1, p < 0.05
by the Chi-square test or Fisher's Exact test). Further anal-
ysis by logistic regression indicated that genotypes at
Table 1: Genotype distributions for the health examination and patient groups.
Location DNA and amino acid 
change
Validation Health examination 
group allele 
distribution
Patient group allele 
distribution
p*
exon 9 g.1050T>G SNP TT = 74 GG = 0 TT = 79 GG = 0 NS#
silent unreported TG = 0 HW$ = 1 TG = 1 HW = 0.955
exon 10 g.1378delG deletion GG = 74 -- = 0 GG = 79 -- = 0 NS
p.E460fs unreported -G- = 0 HW = 1 -G- = 1 HW = 0.955
exon 11 g.1458T>C SNP TT = 2 CC = 41 TT = 5 CC = 62 0.0012
silent rs2229992§ CT = 31 HW = 0.169 CT = 13 HW = 0.002
exon 11 g.1488A>T SNP AA = 73 TT = 0 AA = 80 TT = 0 NS
silent rs9282599§ AT = 1 HW = 0.953 AT = 0 HW = 1
exon 13 g.1635G>A SNP GG = 0 AA = 55 GG = 0 AA = 57 NS**
silent rs351771§ AG = 19 HW = 0.205 AG = 23 HW = 0.133
exon 15 g.3374T>C mutation TT = 73 CC = 0 TT = 77 CC = 0 NS
p.V1125A unreported TC = 1 HW = 0.953 CT = 3 HW = 0.864
exon 15 g.3378C>G mutation CC = 73 GG = 0 CC = 80 GG = 0 NS
p.S1126R unreported CG = 1 HW = 0.953 CG = 0 HW = 1
exon 15 g.4479G>A SNP GG = 2 AA = 49 GG = 0 AA = 69 0.0057
silent rs41115§ AG = 23 HW = 0.718 AG = 11 HW = 0.509
exon 15 g.4725A>G SNP AA = 74 GG = 0 AA = 79 GG = 0 NS
silent unreported AG = 0 HW = 1 AG = 1 HW = 0.955
exon 15 g.5034G>A SNP GG = 7 AA = 44 GG = 2 AA = 59 NS
silent rs42427§ AG = 23 HW = 0.141 AG = 19 HW = 0.753
exon 15 g.5268T>G SNP TT = 7 GG = 44 TT = 0 GG = 63 0.0023
silent rs866006§ GT = 23 HW = 0.141 GT = 17 HW = 0.288
exon 15 g.5465A>T SNP AA = 64 TT = 0 AA = 78 TT = 0 0.0145
p.D1822V rs459552§ AT = 10 HW = 0.533 AT = 2 HW = 0.910
exon 15 g.5880G>A SNP GG = 1 AA = 51 GG = 0 AA = 57 NS
silent rs465899§ AG = 22 HW = 0.418 AG = 23 HW = 0.133
§:The refSNP IDs from NCBI RefSNP Clusters are listed under reported SNPs.
$HW: p value of Hardy-Weinberg equilibrium obtained by Chi-square test.
#NS: Not significant.
*: The difference distribution of genotypes were examined by Chi-square test or Fisher's exact test.
**: The p value was obtained by Chi-square test, and others by Fisher's exact test.BMC Cancer 2006, 6:83 http://www.biomedcentral.com/1471-2407/6/83
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g.1458T>C, g.4479G>A and g.5268T>G had high odds
ratios for CRC (Table 3). These genotypes may therefore
serve as markers predicting the development of CRC. The
polymorphism p.D1822V, which was observed in the
present study, is located in close proximity to the fifth
APC cysteine-rich region β-catenin binding repeat (amino
acids 1840–1866). p.D1822V is a missense variant previ-
ously shown to be a common polymorphism unrelated to
the risk of developing CRC or colorectal adenoma
[18,19]. However, two previous studies of CRC demon-
strated significant gene-environment interactions
between the p.D1822V polymorphism and consumption
of a low-fat diet and postmenopausal hormone use
[19,22]. Although no TT homozygotes for this site were
identified in the present study, AT heterozygotes for this
site were identified who had a low odds ratio for CRC
(Table 3). The presence of a T allele at this site may there-
fore serve to protect against development of CRC.
Certain SNPs of APC genes were previously reported to be
differentially distributed among different populations. Of
the 10 SNPs identified in the present study the only SNP
with a significantly different allele distribution, as deter-
mined by comparison with the East Asian population
through use of the NCBI SNP databank (p <0.05, Chi-
square test), was g.4479G>A. Further analysis revealed
that an AA genotype for this SNP is associated with a
higher risk for CRC. This observation implicates this gen-
otype as a likely marker for CRC in the Taiwanese popula-
tion. The other two SNPs, g.1458T>C and g.5268T>G,
with higher risk genotypes for CRC were not found to
have an allelic distribution different from other East Asian
populations as determined through use of the NCBI SNP
databank. These SNPs may therefore serve as markers for
CRC specific to East Asian populations.
Investigations of the relationships existing between SNPs
or germline mutations in the APC gene and occurrence of
CRC should enable more accurate predictions of CRC.
Furthermore, extensive screening of FAP patients should
lead to a better understanding of the importance of events
underlying development of CRC. Future studies of various
high-risk APC gene mutations may also lead to improve-
Table 2: The characteristics of the patients with 1378delG or 3374T>C.
Patient No. Mutation Sex Age Tumor grade§ Tumor location
p11 g.1378delG male 39 B distal
p40 g.3374T>C male 61 B rectal
p27 g.3374T>C male 52 B proximal
p61 g.3374T>C male 51 C rectal
§: Duke's stage.
Table 3: The ORs for CRC of APC genotypes at g.1458T>C, g.4479G>A, g.5268T>G and g.5465A>T.
Variant Genotype Numbers in healthy/patient 
group
OR (95% CI$) p*
g.1458T>C TT 2/5 1.65 (0.31 – 8.93) NS#
TC 31/13 0.28 (0.13 – 0.59) 0.001
CC 41/62 1
g.4479G>A GG 2/0 0 NS
GA 23/11 0.34 (0.15 – 0.76) 0.009
AA 49/69 1
g.5268T>G TT 7/0 0 NS
TG 23/17 0.52 (0.25 – 1.08) 0.078**
GG 44/63 1
g.5465A>T AA 64/78 1
AT 10/2 0.16 (0.03 – 0.78) 0.023
TT 0/0
$CI: Confidence interval.
*: The p value was obtained by logistic regression.
**: Close to significant.
#NS: Not significant.BMC Cancer 2006, 6:83 http://www.biomedcentral.com/1471-2407/6/83
Page 6 of 6
(page number not for citation purposes)
ments in therapy and, therefore, to increased survival of
CRC patients.
Conclusion
Among the APC  genes of the 154 Taiwanese subjects
examined in this case-control study three new mutations,
but no previously reported mutations, were identified.
Taiwanese subjects therefore appear to differ from other
subjects with respect to the genotypic presentation of
APC. Three high risk genotypes at 3 SNPs and one low risk
genotype at codon 1822 were identified in this study. The
latter was reported previously to have no association with
CRC.
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